203 related articles for article (PubMed ID: 36702528)
1. Risk factors for serious infections in ANCA-associated vasculitis.
Odler B; Riedl R; Gauckler P; Shin JI; Leierer J; Merkel PA; St Clair W; Fervenza F; Geetha D; Monach P; Jayne D; Smith RM; Rosenkranz A; Specks U; Stone JH; Kronbichler A;
Ann Rheum Dis; 2023 May; 82(5):681-687. PubMed ID: 36702528
[TBL] [Abstract][Full Text] [Related]
2. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
3. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
Unizony S; Lim N; Phippard DJ; Carey VJ; Miloslavsky EM; Tchao NK; Iklé D; Asare AL; Merkel PA; Monach PA; Seo P; St Clair EW; Langford CA; Spiera R; Hoffman GS; Kallenberg CG; Specks U; Stone JH
Arthritis Rheumatol; 2015 Feb; 67(2):535-44. PubMed ID: 25332071
[TBL] [Abstract][Full Text] [Related]
4. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
[TBL] [Abstract][Full Text] [Related]
7. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
Kallenberg CG; Hauser T
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Iklé D; Villarreal M; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheumatol; 2014 Nov; 66(11):3151-9. PubMed ID: 25047592
[TBL] [Abstract][Full Text] [Related]
9. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.
Gérard M; de Boysson H; Morello R; Martin-Silva N; Leroux AC; Dumont A; Maigné G; Boutemy J; Khoy K; Mariotte D; Lobbedez T; Aouba A; Deshayes S
Scand J Rheumatol; 2023 Mar; 52(2):161-173. PubMed ID: 35048797
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
14. Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study.
Mendel A; Behlouli H; de Moura CS; Vinet É; Curtis JR; Bernatsky S
Arthritis Res Ther; 2023 Jul; 25(1):133. PubMed ID: 37516897
[TBL] [Abstract][Full Text] [Related]
15. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.
Roccatello D; Sciascia S; Murgia S; Quattrocchio G; Ferro M; De Simone E; Naretto C; Barreca A; Sammartino A; Rossi D; Fenoglio R
Front Immunol; 2022; 13():777134. PubMed ID: 35401565
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
[TBL] [Abstract][Full Text] [Related]
18. Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?
Morel P; Karras A; Porcher R; Belenfant X; Audard V; Rafat C; Hanouna G; Beaudreuil S; Vilain C; Hummel A; Terrier B; Pillebout E; Groh M; Jouenne R; Dhote R; Fain O; Ponsoye M; Noel N; Limal N; Puéchal X; Le Jeunne C; Guillevin L; Mouthon L; Régent A
Rheumatology (Oxford); 2022 Oct; 61(10):4056-4064. PubMed ID: 35108368
[TBL] [Abstract][Full Text] [Related]
19. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
Kronbichler A; Kerschbaum J; Gopaluni S; Tieu J; Alberici F; Jones RB; Smith RM; Jayne DRW
Ann Rheum Dis; 2018 Oct; 77(10):1440-1447. PubMed ID: 29950327
[TBL] [Abstract][Full Text] [Related]
20. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]